Провоспалительные адипокины и цитокины при абдоминальном ожирении как фактор развития атеросклероза и патологии почек

В последние десятилетия наблюдается рост распространенности избыточной массы тела и ожирения. Ожирение стало недооцененной пандемией и угрозой общественному здоровью во всем мире. Жировая ткань позиционируется как эндокринный орган, секретирующий широкий спектр провоспалительных цитокинов и адипокинов, индуцируя состояние хронического субвоспаления. Результаты эпидемиологических исследований за последние 30 лет показали также, что висцеральная жировая ткань является независимым фактором риска развития атеросклероза, кардиометаболических заболеваний и хронической болезни почек. Нами выполнен систематический обзор с целью обобщить важные аспекты состояния хронического субвоспаления в контексте его влияния на снижение скорости клубочковой фильтрации и развитие хронической болезни почек. В обзоре рассмотрены вопросы этиологии и патогенеза ожирения, гормонального профиля жировой ткани, молекулярных механизмов воздействия провоспалительных цитокинов и адипокинов на почки и патофизиологии почечных заболеваний. Использованы сведения по теме из публикаций на основе базы данных Pubmed.

1. Magalhães D.S.C., Pedro J.M.P., Souteiro P.E.B., Neves J.S., Castro-Oliveira S., Bettencourt-Silva R., Costa M.M., Varela A., Queirós J., Freitas P., Carvalho D. Analyzing the impact of bariatric surgery in kidney function: a 2-year observational study. Obes. Surg., 2019; 29 (1): 197–206. doi:10.1007/s11695-018-3508-1

2. Abella V., Scotece M., Conde J., Pino J., GonzalezGay M.A., Gómez-Reino J.J., Mera A., Lago F., Gomez R., Gualillo O. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat. Rev. Rheumatol., 2017, 13: 100–109. doi:10.1038/nrrheum.2016.209

3. Mihalopoulos N.L., Yap J.T., Beardmore B., Holubkov R., Nanjee M.N., Hoffman J.M. Cold-activated brown adipose tissue is associated with less cardiometabolic dysfunction in young adults with obesity. Obesity, 2020; 28: 916–923. doi:10.1002/oby.22767

4. Neeland I., Ross R., Després J.-P., Matsuzawa Y., Yamashita S., Shai I., Seidell J., Magni P., Santos R.D., Arsenault B., Cuevas A., Hu F.B., Griffin B., Zambon A., Barter P., Fruchart J.-C., Eckel R.H. International atherosclerosis society; International chair on cardiometabolic risk working group on visceral obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol., 2019; 7 (9): 715–725. doi:10.1016/S2213-8587(19)30084-1

5. Câmara N.O.S., Iseki K., Kramer H., Sharma Z.-H.-L., Sharma K. Kidney disease and obesity: epidemiology, mechanisms and treatment. Nature Reviews. Nephrology, 2017; 13 (3): 181–190. doi:10.1038/nrneph.2016.191

6. The GBD 2015 obesity collaborators: Afshin A., Forouzanfar M.H., Reitsma M.B., Sur P., Estep K., Lee A., Marczak L., Mokdad A.H., Moradi-Lakeh M., Naghavi M., Salama J.S., Vos T., Abate K.H., Abbafati C., Ahmed M.B., Al-Aly Z., Alkerwi A., AlRaddadi R., Amare A.T., Amberbir A., Amegah A.K., Amini E., Amrock S.M., Anjana R.M., Ärnlöv J., Asayesh H., Banerjee A., Barac A., Baye E., Bennett D.A., Beyene A.S., Biadgilign S., Biryukov S., Bjertness E., Boneya D.J., Campos-Nonato I., Carrero J.J., Cecilio P., Cercy K., Ciobanu L.J., Cornaby L., Damtew S.A., Dandona L., Dandona R., Dharmaratne S.D., Duncan B.B., Eshrati B., Esteghamati A., Feigin V.L., Fernandes J.S., Fürst T., Gebrehiwot T., Gold A., Gona P.N., Goto A., Habtewold D.T., Hadush K.T., Hafezi-Nejad N., Hay S.I., Horino M., Islami F., Kamal R., Kasaeian A., Katikireddi S.V., Kengne A.P., Kesavachandran C.N., Khader Y.S., Khang Y.-H., Khubchandani J., Kim D., Kim Y.J., Kinfu Y., Kosen S., Ku T., Defo B.K., Kumar G.A., Larson H.J., Leinsalu M., Liang X., Lim S.S., Liu P., Lopez A.D., Lozano R., Majeed A., Malekzadeh R., Malta D.C., Mazidi M., McAlinden C., McGarvey S.T., Mengistu D.T., Mensah G.A., Mensink G.B.M., Mezgebe H.B., Mirrakhimov E.M., Mueller U.O., Noubiap J.J., Obermeyer C.M., Ogbo F.A., Owolabi M.O., Patton J.C., Pourmalek F., Qorbani M., Rafay A., Rai R.K., Ranabhat C.L., Reinig N., Safiri S., Salomon J.A., Sanabria J.R., Santos I.S., Sartorius B., Sawhney M., Schmidhuber J., Schutte A.E., Schmidt M.I., Sepanlou S.G., Shamsizadeh M., Sheikhbahaei S., Shin M.-J., Shiri R., Shiue I., Roba H.S., Silva D.A.S., Silverberg J.I., Singh J.A., Stranges S., Swaminathan S., Tabarés-Seisdedos R., Tadese F., Tedla B.A., Tegegne B.S., Terkawi A.S., Thakur J.S., Tonelli M., ToporMadry R., Tyrovolas S., Ukwaja K.N., Uthman O.A., Vaezghasemi M., Vasankari T., Vlassov V.V., Vollset S.E., Weiderpass E., Werdecker A., Wesana J., Westerman R., Yano Y., Yonemoto N., Yonga G., Zaidi Z., Zenebe Z.M., Zipkin B., Murray C.J.L. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med., 2017; 377 (1): 13–27. doi:10.1056/NEJMoa1614362

7. Zorena K., Jachimowicz-Duda O., Slezak D., Robakowska M., Mrugacz M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int. J. Mol. Sci., 2020; 21: 3570. doi:10.3390/ijms21103570

8. Hetta H.F., Ez-Eldeen M.E., Mohamed G.A., Gaber M.A., ElBadre H.M., Ahmed E.A., Abdellatief R.B., Abd-ElBaky R.M., Elkady A., Nafee A.M. Visfatin serum levels in obese type 2 diabetic patients: relation to proinflammatory cytokines and insulin resistance. Egypt J. Immunol., 2018; 25: 141–151. pmid:30600957

9. Fruhbeck G., Kiortsis D.N., Catalan V. Precision medicine: diagnosis and management of obesity. Lancet Diabetes Endocrinol., 2017; 6: 164–166. doi:10.1016/j.mce.2017.04.009

10. Thyagarajan B., Foster M.T. Beiging of white adipose tissue as a therapeutic strategy for weight loss in humans. Hormone Mol. Biol. and Clin. Investigat., 2017; 16. doi:10.1515/hmbci-2017-0016

11. Pahlavani M., Kalupahana N.S., Ramalingam L., Moustaid-Moussa N. Regulation and functions of the renin-angiotensin system in white and brown adipose tissue. Comprehensive Physiol., 2017; 7: 1137–1150. doi:10.1002/cphy.c160031

12. Feijóo-Bandín S., Aragón-Herrera A., MorañaFernández S., Anido-Varela L., Tarazón E., Roselló-Lletí E., Portolés M., Moscoso I., Gualillo O., González-Juanatey J.R., Lago F. Adipokines and inflammation: focus on cardiovascular diseases. Int. J. Mol. Sci., 2020; 21: 7711. doi:10.3390/ijms21207711

13. Horimatsu T., Kim H.W., Weintraub N.L. The role of perivascular adipose tissue in non-atherosclerotic vascular disease. Front. Physiol., 2017; 8: 969. doi:10.3389/fphys.2017.00969

14. Francisco V., Pino J., Gonzalez-Gay M.A., Mera A., Lago F., Gómez R., Mobasheri A., Gualillo O. Adipokines and inflammation: is it a question of weight? British J. of Pharmacol., 2018; 175: 1569–1579. doi:10.1111/bph.14181

15. Ding Y., Xian X., Holland W.L., Tsai S., Herz J. Low-density lipoprotein receptor-related protein-1 protects against hepatic insulin resistance and hepatic steatosis. EBioMedicine, 2016; 7: 135–145. doi:10.1016/j.ebiom.2016.04.002

16. Rebecchi F., Allaix M.E., Patti M.G., Schlottmann F., Morino M. Gastroesophageal reflux disease and morbid obesity: to sleeve or not to sleeve? World J. Gastroenterol., 2017; 23 (13): 2269–2275. doi:10.3748/wjg.v23.i13.2269

17. Villarroya F., Cereijo R., Gavaldà-Navarro A., Villarroya J., Giralt M. Inflammation of brown/beige adipose tissues in obesity and metabolic disease. J. Intern. Med., 2018; 284: 492–504. doi:10.1111/joim.12803

18. Rodriguez A., Becerril S., Ezquerro S., MendezGimenez L., Fruhbeck G. Cross-talk between adipokines and myokines in fat browning. Acta Physiol., 2017; 219: 362–381. doi:10.1111/apha.12686

19. Bateman A., Cheung S.T., Bennett H.P.J. A brief overview of progranulin in health and disease. Methods in Mol. Biol., 2018. doi:10.1007/978-1-4939-8559-3_1

20. Favre G., Anty R., Canivet C. Determinants associated with the correction of glomerular hyper-filtration one year after bariatric surgery. Surg. Obes. Relat. Dis., 2017; 13 (10): 1760–1766. doi:10.1016/j.soard.2017.07.018

21. Abella V., Pino J., Scotece M., Conde J., Lago F., Gonzalez-Gay M.A. Progranulin as a biomarker and potential therapeutic agent. Drug Discov. Today, 2017; 22: 1557–1564. doi:10.1016/j.drudis.2017.06.006

22. Cebeci E., Çakan C., Gursu M., Uzun S., Karada G.S., Kolda S.M., Çalhan T., Helvaci S.A., Öztürk S. The main determinants of serum resistin level in type 2 diabetic patients are renal function and inflammation not presence of microvascular complication, obesity and insulin resistance. Exp. Clin. Endocrinol. Diabetes, 2018; 127: 189–194. doi:10.1055/s-0043-121262

23. Lynch M., Ahern T., Sweeney C.M., Malara A., Tobin A.M., O’Shea D., Kirby B. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int. J. Dermatol., 2017; 56 (11): 1103–1118. doi:10.1111/ijd.13699

24. Davis F.M., Gallagher K.A. Epigenetic mechanisms in monocytes/macrophages regulate inflammation in cardiometabolic and vascular disease. Arterioscler. Thromb. Vasc. Biol., 2019; 39 (4): 623–634. doi:10.1161/ATVBAHA.118.312135

25. Konaniah E.S., Kuhel D.G., Basford J.E., Weintraub N.L., Hui D.Y. Deficiency of LRP1 in mature adipocytes promotes diet-induced inflammation and atherosclerosis–brief report. Arteriosclerosis, Thrombosis, and Vascular. Biol., 2017; 37 (6): 1046–1049. doi:10.1161/ATVBAHA.117.309414

26. Recinella L., Orlando G., Ferrante C., Chiavaroli A., Brunetti L. Leone S. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front. Physiol., 2020; 11. doi:10.3389/fphys.2020.578966

27. Djudjaja S., Boora P. Cellular and molecular mechanisms of kidney fibrosis. Mol. Aspects of Medicine, 2018; 6. doi:10.1016/j.mam.2018.06.002

28. Lu C.-C., Wang G.-H., Lu J., Chen P.-P., Zhang Y., Hu Z.-B., Ma K.-L. Role of podocyte injury in glomerulosclerosis. Renal Fibrosis: Mechanisms and Therapies, Adv. Exp. Med. Biol., 2019; 1165: 195–232. doi:10.1007/978-981-13-8871-2_10

29. Dumas D.L.R.C. Actualite´ sur les me´ canismes physiopathologiques des syndromes ne´phrotiques idiopathiques: le´ sions glome´ rulaires minimes et hyalinose segmentaire et focale. Ne´phrol. Ther., 2018; 14 (7). doi:10.1016/j.nephro.2018.06.001

30. Rayego-Mateos S., Valdivielso J.M. New therapeutic targets in chronic kidney disease progression and renal fibrosis. Expert Opinion on Therapeutic Targets, 2020. doi:10.1080/14728222.2020.1762173

31. Nogueira A., Pires M.J., Oliviera P.A. Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies. In vivo, 2017; 31: 1–22. doi:10.21873/invivo.11019

32. Wakamatsu K., Seki Y., Kasama K., Uno K., Hashimoto K., Seto Y., Kurokawa Y. Prevalence of chronic kidney disease in morbidly obese Japanese and the impact of bariatric surgery on disease progression. Obesity Surgery, 2017. doi:10.1007/s11695-017-2863-7

33. Favre G. Longitudinal assessment of renal function in native kidney after bariatric surgery. Surgery for Obesity and Related Diseases, 2018. doi:10.1016/j.soard.2018.05.013

34. Park H.K., Kwak M.K., Kim H.J., Ahima R.S. Linking resistin, inflammation, and cardiometabolic diseases. Korean J. Intern. Med., 2017; 32: 239–247. doi:10.3904/kjim.2016.229

35. Andrade-Oliveira V., Foresto-Neto O., Watanabe I.K.M. Inflammation in renal diseases: new and old players. Front. Pharmacol., 2019; 10: 1192. doi:10.3389/fphar.2019.01192

36. Zeng L.F., Xiao Y., Sun L. A glimpse of the mechanisms related to renal fibrosis in diabetic nephropathy. Adv. Exp. Med. Biol., 2019; 1165: 49–79. doi:10.1007/978-981-13-8871-2_4

37. Chang A.R., Grams M.E., Navaneethan S.D. Bariatric surgery and kidney-related outcomes. Kidney Int. Rep., 2017; 2 (2): 261–270. doi:10.1016/j.ekir.2017.01.010

38. Orellana J.M., Kampe K., Schulze F., Sieber J., Jehle A.W. Fetuin-A aggravates lipotoxicity in podocytes via interleukin-1 signaling. Physiol. Rep., 2017; 5. doi:10.14814/phy2.13287

39. Wilson P.C., Kashgarian M., Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin. Kidney J., 2018; 11 (2): 207–218. doi: 10.1093/ckj/sfx093

40. Gu Y.-Y., Liu X.-S., Huang X.-R., Yu X.-Q., Lan H.-Y. TGF-β in renal fibrosis: triumphs and challenges. Future Med. Chem., 2020; 12 (9): 853–866. doi:10.4155/fmc-2020-0005

41. Choi S.Y., Lim S.W., Salimi S., Yoo E.J., LeeKwon W., Lee H.H. Tonicity-responsive enhancerbinding protein mediates hyperglycemia-induced inflammation and vascular and renal injury. J. Am. Soc. Nephrol., 2018; 29: 492–504. doi:10.1681/ASN.2017070718

42. Nosalski R., Guzik T.J. Perivascular adipose tissue inflammation in vascular disease. British J. Pharmacol., 2017; 174: 3496–3513. doi:10.1111/bph.13705

43. Nehus E. Obesity and chronic kidney disease. Curr. Opin. Pediatr., 2018; 30. doi:10.1097/MOP.0000000000000586

44. Mehta N., Gava A.L., Zhang D. Follistatin protects against glomerular mesangial cell apoptosis and oxidative stress to ameliorate chronic kidney disease. Antioxid Redox Signal, 2019; 31: 551–571. doi:10.1089/ars.2018.7684

45. Gaillard M., Tranchart H., Beaudreuil S., Lebrun A., Voican C.S., Lainas P., Courie R., Perlemuter G., Parier B., Hammoudi Y., Durrbach A., Dagher I. Laparoscopic sleeve gastrectomy for morbid obesity in renal transplantation candidates: a matched case–control study. Transplant International, 2020; 33: 1061– 1070. doi:10.1111/tri.13637

46. Aggarwal H.K., Jain D., Chauda R., Bhatia S., Sehgal R. Assessment of malnutrition inflammation score in different stages of chronic kidney disease. Pril. (Makedon. Akad. Nauk. Umet. Odd. Med. Nauk.), 2018; 39: 51–61. doi:10.2478/prilozi-2018-0042

47. Lin Y.-C., Lai Y.-J., Lin Y.-C., Peng C.-C., Chen K.- C., Chuang M.-T., Wu M.-S., Chang T.-H. Effect of weight loss on the estimated glomerular filtration rates of obese patients at risk of chronic kidney disease: the RIGOR-TMU study. J. Cachexia, Sarcopenia and Muscle, 2019. doi:10.1002/jcsm.12423

48. Liu M., Ning X., Li R. Signalling pathways involved in hypoxia-induced renal fibrosis. J. Cell. Mol. Med., 2017; 21 (7): 1248–1259. doi:10.1111/jcmm.13060